Skip to main
AARD

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Aardvark Therapeutics Inc's positive outlook is supported by the expansion of eligibility criteria for its Phase 3 HERO trial of ARD-101, lowering the age limit from 10 to 7 for patients with Prader Willi Syndrome (PWS), thereby increasing the potential patient population. Despite a revised likelihood of success at 50% and an extended potential product launch timeline to 2029, the company continues to explore additional avenues for tackling general obesity, positioning itself competitively against injectable GLP-1 therapeutics. Furthermore, the anticipation of topline data expected in Q3 2026 highlights Aardvark's proactive steps in advancing its clinical programs, which may enhance investor confidence and drive future growth.

Bears say

The analysis indicates a negative outlook for Aardvark Therapeutics's stock due to several fundamental concerns surrounding its lead product candidate, ARD-101. Key issues include potential delays in the HERO trial timeline, regulatory uncertainties, and the risk of negative clinical results, which could hinder the company's progress and market presence. Additionally, the presence of multiple risks, including competitive market pressures and possible share dilution from financing activities, contributes to a pessimistic financial perspective on the firm's future viability.

AARD has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Buy based on their latest research and market trends.

According to 8 analysts, AARD has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.